阿利西尤单抗联合瑞舒伐他汀在冠心病患者降脂治疗中的效果及对炎症因子、心功能和预后的影响  

Effect of aliximab combined with rosuvastatin on lipid-lowering therapy in patients with coronary heart disease and their influence on inflammatory factors,cardiac function and prognosis

作　　者：党宏伟[1] 冯卫涛 DANG Hong-wei;FENG Wei-tao(Department of Cardiovascular Medicine,Baoji Central Hospital,Baoji Shaanxi 721000,China;Department of Internal Medicine,Shaanxi Rongfu Military First Hospital,Baoji Shaanxi 721300,China)

机构地区：[1]宝鸡市中心医院心血管内科,陕西宝鸡721000 [2]陕西省荣复军人第一医院内科,陕西宝鸡721300

出　　处：《临床和实验医学杂志》2024年第23期2470-2474,共5页Journal of Clinical and Experimental Medicine

基　　金：陕西省教育厅科研基金项目(编号:16JK1648)。

摘　　要：目的探讨阿利西尤单抗联合瑞舒伐他汀在冠心病患者降脂治疗中的效果及对炎症因子、心功能和预后的影响。方法前瞻性选取2022年1月至2023年12月宝鸡市中心医院收治的82例冠心病患者作为研究对象。按照随机数字表法将其分为观察组与对照组,每组各41例。对照组给予瑞舒伐他汀治疗,观察组给予阿利西尤单抗联合瑞舒伐他汀治疗,两组均治疗6个月。对两组治疗前和治疗后6个月血脂[总胆固醇、甘油三酯和低密度脂蛋白胆固醇(LDL-C)]水平、血清炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)]和心功能指标[左心室舒张末期内径(LVEDD)、左室射血分数(LVEF)、血清N末端B型脑钠利肽前体(NT-proBNP)]进行对比分析,比较两组主要不良心血管事件(MACE)发生率和不良反应。结果治疗后6个月,两组的总胆固醇、甘油三酯、LDL-C水平均较治疗前明显下降,且观察组的总胆固醇、甘油三酯、LDL-C水平分别为(3.21±0.75)、(1.39±0.51)、(1.71±0.55)mmol/L,均低于对照组[(3.78±0.91)、(1.78±0.57)、(2.17±0.51)mmol/L],差异均有统计学意义(P<0.05)。治疗后6个月,两组的hs-CRP、IL-6水平均较治疗前明显下降,且观察组的hs-CRP、IL-6水平分别为(5.17±1.34)mg/L、(7.52±1.67)ng/L,均低于对照组[(7.46±1.67)mg/L、(9.11±1.87)ng/L],差异均有统计学意义(P<0.05)。治疗后6个月,两组的LVEDD和血清NT-proBNP水平均较治疗前明显下降,LVEF均较治疗前明显升高,且LVEDD和血清NT-proBNP水平分别为(52.78±4.49)mm、(464.36±136.58)ng/L,均低于对照组[(54.32±4.61)mm、(625.36±201.68)ng/L],观察组的LVEF为(56.17±4.25)%,显著高于对照组[(54.29±4.07)%],差异均有统计学意义(P<0.05)。观察组MACE发生率为24.39%,低于对照组(7.32%),差异有统计学意义(P<0.05)。观察组与对照组组间不良反应发生率比较(12.20%vs.7.32%),差异无统计学意义(P>0.05)。结论冠心病患者使用阿利西尤单抗与Objective To investigate the effect of alixiumab combined with rosuvastatin on lipid-lowering therapy in patients with coronary heart disease and their influence on inflammatory factors,cardiac function and prognosis.Methods A total of 82 patients with coronary heart disease admitted to Baoji Central Hospital from January 2022 to December 2023 were prospectively selected as the study subjects.According to the random number table method,they were divided into the observation group and the control group,41 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with alixiyumab combined with rosuvastatin.Both groups were treated for 6 months.The blood lipid[total cholesterol,triglycerides and low density lipoprotein cholesterol(LDL-C)]levels,serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)]and cardiac function indexes[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),serum N-terminal B-type natriuretic peptide precursor(NT-proBNP)]before treatment and 6 months after treatment were compared between the two groups.The major adverse cardiovascular events(MACE)incidence and adverse reactions between the two groups were compared.Results At 6 months after treatment,the levels of total cholesterol,triglyceride and LDL-C in the two groups were significantly lower than those before treatment,and the levels of total cholesterol,triglyceride and LDL-C in the observation group were(3.21±0.75),(1.39±0.51)and(1.71±0.55)mmol/L,respectively,which were lower than those in the control group[(3.78±0.91),(1.78±0.57)and(2.17±0.51)mmol/L],the differences were statistically significant(P<0.05).At 6 months after treatment,the levels of hs-CRP and IL-6 in the two groups were significantly lower than those before treatment,and the levels of hs-CRP and IL-6 in the observation group were(5.17±1.34)mg/L and(7.52±1.67)ng/L,respectively,which were lower than those in the control group[(7.46±1.67)mg/L,(9.11±1.

关 键 词：冠心病 阿利西尤单抗 瑞舒伐他汀 炎症因子 心功能 预后 

分 类 号：R54[医药卫生—心血管疾病]